Transanal Irrigation for Low Anterior Resection Syndrome

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jan 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of transanal irrigation (TAI) as a potential treatment for patients experiencing Low Anterior Resection Syndrome (LARS) after surgery for rectal cancer. LARS can cause uncomfortable bowel symptoms like diarrhea and urgent bowel movements, which can significantly affect a person’s quality of life, especially their sleep. The researchers want to find out if TAI, which involves using water to clean the rectum, can help reduce these symptoms and improve sleep quality for patients dealing with LARS.

To be eligible for the trial, participants need to be adults aged 19 and older who have had specific types of rectal cancer surgery at least two years ago and do not have a permanent colostomy. They should also have a significant LARS score indicating their symptoms. However, people with certain conditions, like recurrent cancer or severe bowel issues, will not be able to participate. If you join the trial, you can expect to follow a specific treatment plan and share your experiences, which will help researchers understand how effective TAI might be for managing LARS symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 19 years and above.
• • Patients who have undergone low or ultra-low anterior resection surgery for rectal cancer (within 15cm from the anal verge).
• • Patients at least 24 months post-surgery without stoma.
• • Patients evaluated with a major LARS score.
• • Patients who comprehend and have the ability to participate in this clinical trial.
• Exclusion Criteria:
• • Patients with recurrent colorectal cancer.
• • Patients with concomitant metastatic colorectal cancer.
• • Patients requiring permanent colostomy.
• • Patients who have undergone postoperative cancer radiation therapy.
• • Patients with underlying conditions not controlled by internal medical treatment.
• • Patients with inflammatory bowel disease (IBD).
• • Patients with symptoms of constipation or diarrhea not controlled by medication.
• • Patients with preoperative symptoms of fecal incontinence.
• • Patients allergic to the investigational drug.
• • Patients deemed unsuitable for clinical trial participation by the principal investigator and study personnel.